Amphista Advances Targeted Glue™ Degraders with Novel E3 Ligases, Clinical Candidate on Track for H2 2026
Event summary
- Amphista presented new data at Keystone Symposia demonstrating its Eclipsys® platform's ability to develop Targeted Glue™ degraders using novel E3 ligases, including DCAF11 for KRAS G12D degradation.
- First clinical candidate, AMX-883, a DCAF16-dependent Targeted Glue™ degrader of BRD9, is set to enter Phase 1 trials in H2 2026 for AML treatment.
- Amphista has successfully integrated Targeted Glues™ into degrader-antibody-conjugates (DACs), expanding beyond traditional small molecule approaches.
- The Eclipsys® platform combines CryoEM, geometric deep learning, and cheminformatics to enhance molecular glue degrader development.
The big picture
Amphista’s progress in developing Targeted Glue™ degraders using novel E3 ligases positions it as a leader in next-generation protein degradation therapies. The shift away from traditional cereblon/VHL-based approaches could open new therapeutic avenues in oncology and neurodegenerative diseases. The company’s ability to integrate these degraders into DACs further expands its potential applications, though success will depend on clinical validation and competitive differentiation.
What we're watching
- Clinical Execution
- Whether AMX-883 can demonstrate efficacy and safety in Phase 1 trials for AML, validating Amphista’s novel approach.
- Pipeline Expansion
- The pace at which Amphista can advance additional Targeted Glue™ candidates into the clinic beyond AMX-883.
- Competitive Positioning
- How Amphista’s novel E3 ligase recruitment strategy differentiates it from cereblon/VHL-based degraders in the market.
Related topics